A study to evaluate the immune response and safety of AdCOVID administered as an intranasal spray in healthy adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
92
AGA Clinical Trials
Hialeah, Florida, United States
Optimal Research
Melbourne, Florida, United States
Optimal Research
Peoria, Illinois, United States
Optimal Research
Rockville, Maryland, United States
Reactogenicity
Counts and percentages of subjects with local and systemic events
Time frame: For 7 days after vaccination
Adverse Events (AEs)
Counts and percentages of subjects with AEs
Time frame: Day 1 to Day 57
Anti-SARS-CoV-2 spike IgG antibody levels
Time frame: Day 1 to Day 366
Neutralizing antibody titer against live and/or pseudotyped SARS-CoV-2 virus
Time frame: Day 1 to Day 366
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Optimal Research
Austin, Texas, United States
Clinical Trials of Texas
San Antonio, Texas, United States